Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Phase 2 Study of Fosbretabulin Tromethamine (CA4P) for the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic Pancreatic or Gastrointestinal Neuroendocrine Tumors/Carcinoid with Elevated Biomarkers Libutti, S. K., Anthony, L., Sosa, J., Kunz, P., Thomas, J., Cruikshank, S., Varga, A., Chaplin, D. J., Burke, J., Wolin, E. M. LIPPINCOTT WILLIAMS & WILKINS. 2016: 478
View details for Web of Science ID 000370956600059